Remedium Lifecare Ltd
₹ 5.21
0.19%
20 Dec
- close price
About
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
Key Points
- Market Cap ₹ 210 Cr.
- Current Price ₹ 5.21
- High / Low ₹ 38.2 / 5.01
- Stock P/E 11.4
- Book Value ₹ 1.14
- Dividend Yield 0.00 %
- ROCE 99.5 %
- ROE 123 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 405% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 101%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 1.11%
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.19.7 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 1 | 2 | 4 | 1 | 0 | 0 | 3 | 90 | 505 | 510 | 4,040 | 3,345 | |
1 | 1 | 2 | 4 | 1 | 0 | 0 | 2 | 89 | 503 | 502 | 4,006 | 3,321 | |
Operating Profit | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 0 | 1 | 2 | 8 | 34 | 25 |
OPM % | 7% | 3% | -8% | -8% | -7% | 0% | -44% | 14% | 1% | 0% | 2% | 1% | 1% |
0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 | 20 | |
Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 7 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 50 | 38 |
Tax % | 0% | 50% | 21% | 0% | 0% | 0% | 100% | 24% | 26% | 29% | 27% | 35% | |
0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 33 | 18 | |
EPS in Rs | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.13 | 0.81 | 0.46 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 659% |
3 Years: | 255% |
TTM: | 218% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 405% |
3 Years: | 309% |
TTM: | 117% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 92% |
3 Years: | 62% |
1 Year: | -79% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 88% |
3 Years: | 101% |
Last Year: | 123% |
Balance Sheet
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 10 | 40 |
Reserves | -0 | -0 | -1 | -1 | -1 | -1 | -1 | -0 | 0 | 1 | 7 | 33 | 6 |
1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 | 58 | 181 | |
2 | 1 | 3 | 2 | 0 | 0 | 0 | 1 | 24 | 219 | 1,144 | 1,847 | 1,924 | |
Total Liabilities | 6 | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 2,152 |
2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
4 | 4 | 4 | 5 | 3 | 3 | 4 | 4 | 38 | 224 | 1,154 | 1,948 | 2,152 | |
Total Assets | 6 | 6 | 6 | 5 | 3 | 3 | 4 | 4 | 39 | 224 | 1,154 | 1,948 | 2,152 |
Cash Flows
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | -1 | 0 | -0 | -0 | -0 | -10 | 11 | 20 | -74 | |||
0 | 1 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | 0 | |||
-0 | -0 | 0 | 0 | 0 | 0 | 10 | -11 | -0 | 54 | |||
Net Cash Flow | -0 | 0 | 0 | -0 | 1 | -0 | -0 | 1 | 20 | -20 |
Ratios
Figures in Rs. Crores
Mar 2006 | Mar 2007 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 203 | 120 | 341 | 265 | 596 | 2,117 | 319 | 189 | 96 | 46 | 123 | 83 |
Inventory Days | 1,506 | 1,129 | 243 | 78 | 0 | 0 | 5 | 12 | ||||
Days Payable | 162 | 102 | 438 | 129 | 62 | 65 | ||||||
Cash Conversion Cycle | 1,547 | 1,147 | 146 | 214 | 596 | 2,117 | 319 | 189 | 96 | 46 | 67 | 30 |
Working Capital Days | 607 | 566 | 107 | 200 | 524 | 2,159 | 4,745 | 323 | 54 | 2 | -8 | 9 |
ROCE % | 1% | 1% | 0% | 1% | 1% | 11% | 7% | 18% | 103% | 100% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Nov - Newspaper clipping regarding publication of Unaudited Financial Results for quarter and half year ended 30th September 2024.
- Results For The Quarter And Half Year Ended September 30, 2024. 14 Nov
-
Board Meeting Outcome for For Meeting Held On Thursday, November 14, 2024.
14 Nov - Approved unaudited financial results for Q2 FY2024.
-
Board Meeting Intimation for 1) Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2024.
2) Any Other Business With The Permission Of The Chair.
9 Nov - Board meeting scheduled to approve financial results.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Reconstitution Of Committees Of The Board
31 Oct - Reconstitution of Board Committees approved by the Board.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets